The chemical class known as SETD3 Inhibitors comprises a diverse range of compounds that can inhibit the activity of SET Domain Containing 3 (SETD3), a protein involved in the methylation of non-histone proteins such as actin. These inhibitors do not target SETD3 directly; instead, they exert their influence by modulating various signaling pathways and cellular processes that are crucial for the functional role of SETD3. The inhibitors in this class achieve their effect by altering the dynamics of cellular signaling, affecting the phosphorylation status of proteins, and modifying the cellular signaling environment where SETD3 operates. The complexity of these pathways and the interplay of various cellular processes underscore the intricate nature of SETD3's regulation and function within the cell.
The inhibitors affect SETD3's activity by targeting key regulatory pathways that influence epigenetic regulation, chromatin remodeling, and cytoskeletal dynamics. By modulating the activity of enzymes involved in histone modification, DNA methylation, and kinase signaling, these compounds can indirectly influence the methylation of non-histone proteins, including actin, which is a key substrate of SETD3. The impact of these inhibitors extends beyond the immediate enzymatic activity of SETD3, affecting broader cellular processes such as gene expression regulation, cytoskeletal organization, and intracellular signaling. The ability of these inhibitors to interact with multiple pathways and to influence the regulation of key cellular processes highlights their potential significance in understanding the complex regulatory mechanisms in which SETD3 is involved. This indirect approach to modulating SETD3's activity reflects a deepening understanding of the interconnected nature of cellular signaling networks and the critical role of enzymes like SETD3 in maintaining cellular homeostasis and function. The study and development of SETD3 inhibitors offer insights into the diverse regulatory mechanisms at play in cellular biology and provide a foundation for exploring novel approaches to influence key molecular processes within the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Inhibits histone deacetylases and could possibly inhibit SETD3 by affecting chromatin remodeling and epigenetic regulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Inhibits the PI3K/Akt pathway and could possibly inhibit SETD3 by influencing cell signaling and processes. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits mTOR signaling and could possibly inhibit SETD3 by impacting pathways in protein synthesis. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Blocks calcium channels and could possibly inhibit SETD3 by affecting intracellular signaling and processes. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Inhibits tyrosine kinases and could possibly inhibit SETD3 by affecting cell signaling pathways. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
Inhibits NF-κB signaling and could possibly inhibit SETD3 by impacting cellular processes. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Inhibits GSK-3β and could possibly inhibit SETD3 by affecting signaling pathways. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
Inhibits the Wnt/β-catenin signaling pathway and could possibly inhibit SETD3 by influencing related processes. | ||||||